MedTrace Logo

Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine

NCT04179474 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-03-10

Study results available
· View outcomes & findings →

Summary

This study will evaluate the potential for a pharmacokinetic (PK) interaction and provide safety and tolerability information when ubrogepant and erenumab or ubrogepant and galcanezumab are co-administered.

Conditions

Interventions

DRUG

Ubrogepant

Oral administration of 100 mg ubrogepant tablet once daily \[Intervention A=single dose and Intervention D=repeated daily dose\].

DRUG

Erenumab

Single dose subcutaneous (SC) injection of erenumab 140 mg \[Intervention B\].

DRUG

Galcanezumab

2 SC injections of galcanezumab 120 mg \[Intervention C\].

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Ramesh Boinpally · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-26
Primary Completion
2019-12-23
Completion
2019-12-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04179474 on ClinicalTrials.gov